论文部分内容阅读
Lomefloxacin(NY-198)是日本北陆公司研制的新喹诺酮类抗菌剂,由北陆和盐野义公司联合开发,日本千寿公司也在研究中。日本从1985年12月开始组织了全国150个单位对本品进行了广泛研究,1987年5月21～23日在森冈召开的第35次日本化学疗法学会总会上对本品进行了专题报告,发表了131篇研究报告。1987年7月19～24日在土耳其伊斯坦布尔召开的第15次ICC会议上又进一步做了介绍。1988年6月日本化学疗法学会出版了专集,分别对基础研究和临床研究进行了全面介绍。美国Serle公司认为从市场观点看本品潜力很大,是个有希望的新品种。所以该公司由北陆公司获得本品许可证,目前该公司
Lomefloxacin (NY-198) is a new quinolone antibacterial agent developed by Japan’s Hokuriku Co., Ltd. It is jointly developed by Hokuriku and Yasuhiko Yasuhiro and is under research by Japan’s Chisso Corporation. Japan from December 1985 began organizing a nationwide 150 units of this product were extensively studied, May 21-23, 1987 held in Morioka 35th Japan Society of Chemotherapy Society of the topic of this product Report, published 131 research reports. Further briefings were made at the 15th ICC meeting held in Istanbul, Turkey, from July 19 to July 24, 1987. June 1988 Japan Society of Chemotherapy published a special collection, respectively, for basic research and clinical research were fully described. The United States Serle think this product from the market point of view great potential, is a promising new breed. Therefore, the company obtained this product license by Hokuriku Co., Ltd. Currently, the company